We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
DaVita HealthCare (DVA) Beats Stock Market Upswing: What Investors Need to Know
Read MoreHide Full Article
DaVita HealthCare (DVA - Free Report) ended the recent trading session at $149.98, demonstrating a +1.19% change from the preceding day's closing price. This move outpaced the S&P 500's daily gain of 0.25%. Meanwhile, the Dow gained 0.1%, and the Nasdaq, a tech-heavy index, added 0.47%.
Shares of the kidney dialysis provider witnessed a loss of 0.49% over the previous month, beating the performance of the Medical sector with its loss of 4.79%, and the S&P 500's loss of 1.88%.
The investment community will be paying close attention to the earnings performance of DaVita HealthCare in its upcoming release. The company is forecasted to report an EPS of $2.41, showcasing a 20.5% upward movement from the corresponding quarter of the prior year. At the same time, our most recent consensus estimate is projecting a revenue of $3.3 billion, reflecting a 2.36% rise from the equivalent quarter last year.
Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of $14.16 per share and revenue of $14.11 billion. These totals would mark changes of +31.35% and +3.41%, respectively, from last year.
Investors should also pay attention to any latest changes in analyst estimates for DaVita HealthCare. These recent revisions tend to reflect the evolving nature of short-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. DaVita HealthCare currently has a Zacks Rank of #2 (Buy).
In terms of valuation, DaVita HealthCare is presently being traded at a Forward P/E ratio of 10.47. This signifies a discount in comparison to the average Forward P/E of 18.77 for its industry.
Also, we should mention that DVA has a PEG ratio of 0.52. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. DVA's industry had an average PEG ratio of 1.94 as of yesterday's close.
The Medical - Outpatient and Home Healthcare industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 192, placing it within the bottom 22% of over 250 industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
DaVita HealthCare (DVA) Beats Stock Market Upswing: What Investors Need to Know
DaVita HealthCare (DVA - Free Report) ended the recent trading session at $149.98, demonstrating a +1.19% change from the preceding day's closing price. This move outpaced the S&P 500's daily gain of 0.25%. Meanwhile, the Dow gained 0.1%, and the Nasdaq, a tech-heavy index, added 0.47%.
Shares of the kidney dialysis provider witnessed a loss of 0.49% over the previous month, beating the performance of the Medical sector with its loss of 4.79%, and the S&P 500's loss of 1.88%.
The investment community will be paying close attention to the earnings performance of DaVita HealthCare in its upcoming release. The company is forecasted to report an EPS of $2.41, showcasing a 20.5% upward movement from the corresponding quarter of the prior year. At the same time, our most recent consensus estimate is projecting a revenue of $3.3 billion, reflecting a 2.36% rise from the equivalent quarter last year.
Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of $14.16 per share and revenue of $14.11 billion. These totals would mark changes of +31.35% and +3.41%, respectively, from last year.
Investors should also pay attention to any latest changes in analyst estimates for DaVita HealthCare. These recent revisions tend to reflect the evolving nature of short-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. DaVita HealthCare currently has a Zacks Rank of #2 (Buy).
In terms of valuation, DaVita HealthCare is presently being traded at a Forward P/E ratio of 10.47. This signifies a discount in comparison to the average Forward P/E of 18.77 for its industry.
Also, we should mention that DVA has a PEG ratio of 0.52. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. DVA's industry had an average PEG ratio of 1.94 as of yesterday's close.
The Medical - Outpatient and Home Healthcare industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 192, placing it within the bottom 22% of over 250 industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.